Full Text:   <3042>

CLC number: R735.7

On-line Access: 

Received: 2006-10-13

Revision Accepted: 2007-02-07

Crosschecked: 0000-00-00

Cited: 2

Clicked: 5428

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2007 Vol.8 No.4 P.217-220


Vascular architecture: is it a helpful histopathological biomarker for hepatocellular carcinoma?

Author(s):  GRIZZI Fabio, FRANCESCHINI Barbara, FIAMENGO Barbara, RUSSO Carlo, DIOGUARDI Nicola

Affiliation(s):  Laboratories of Quantitative Medicine, Istituto Clinico Humanitas IRCCS, 20089 Rozzano, Milan, Italy; more

Corresponding email(s):   fabio.grizzi@humanitas.it

Key Words:  Liver, Angiogenesis, Cancer, Fractals, Geometry, Biomarkers

Share this article to: More |Next Article >>>

GRIZZI Fabio, FRANCESCHINI Barbara, FIAMENGO Barbara, RUSSO Carlo, DIOGUARDI Nicola. Vascular architecture: is it a helpful histopathological biomarker for hepatocellular carcinoma?[J]. Journal of Zhejiang University Science B, 2007, 8(4): 217-220.

@article{title="Vascular architecture: is it a helpful histopathological biomarker for hepatocellular carcinoma?",
author="GRIZZI Fabio, FRANCESCHINI Barbara, FIAMENGO Barbara, RUSSO Carlo, DIOGUARDI Nicola",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T Vascular architecture: is it a helpful histopathological biomarker for hepatocellular carcinoma?
%A RUSSO Carlo
%J Journal of Zhejiang University SCIENCE B
%V 8
%N 4
%P 217-220
%@ 1673-1581
%D 2007
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2007.B0217

T1 - Vascular architecture: is it a helpful histopathological biomarker for hepatocellular carcinoma?
A1 - GRIZZI Fabio
A1 - FIAMENGO Barbara
A1 - RUSSO Carlo
J0 - Journal of Zhejiang University Science B
VL - 8
IS - 4
SP - 217
EP - 220
%@ 1673-1581
Y1 - 2007
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2007.B0217

Hepatocellular carcinoma (HCC) remains one of the major public health problems throughout the world. Although originally associated with tumorigenic processes, liver angiogenesis has also been observed in the context of different liver inflammatory, fibrotic, and ischemic conditions. Here we investigate the fractal dimension as a quantitator of non-Euclidean two-dimensional vascular geometry in a series of paired specimens of primary HCC and surrounding non-tumoral tissue, and discuss why this parameter might provide additional information regarding cancer behavior. The application of fractal geometry to the measurement of liver vascularity and the availability of a computer-aided quantitative method can eliminate errors in visual interpretation, and make it possible to obtain closer-to-reality numerals that are compulsory for any measurement process.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1] Carmeliet, P., 2003. Angiogenesis in health and disease. Nat. Med., 9(6):653-660.

[2] Farazi, P.A., DePinho, R.A., 2006. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer, 6(9):674-687.

[3] Grizzi, F., Chiriva-Internati, M., 2006. Cancer: looking for simplicity and finding complexity. Cancer Cell Int., 6(1):4.

[4] Grizzi, F., Colombo, P., Barbieri, B., Franceschini, B., Roncalli, M., Chiriva-Internati, M., Muzzio, P.C., Dioguardi, N., 2001. Correspondence re: E. Sabo et al., Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin. Cancer Res., 7:533-537, 2001. Clin. Cancer Res., 7(10):3305-3307.

[5] Grizzi, F., Franceschini, B., Hamrick, C., Frezza, E.E., Cobos, E., Chiriva-Internati, M., 2007. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J. Transl. Med., 5(1):3.

[6] Hand, D.J., 2004. Measurement: Theory and Practice. Arnold, New York.

[7] Hlatky, L., Hahnfeldt, P., Folkman, J., 2002. Clinical application of antiangiogenic therapy: microvessel density, what it does and does not tell us. J. Natl. Cancer Inst., 94(12):883-893.

[8] Jain, R.K., 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307(5706):58-62.

[9] Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J., Thun, M.J., 2005. Cancer statistics, 2005. CA Cancer J. Clinicians, 55(1):10-30.

[10] Mandelbrot, B.B., 1983. The Fractal Geometry of the Nature. Freeman, San Francisco.

[11] Marion-Audibert, A.M., Barel, C., Gouysse, G., Dumortier, J., Pilleul, F., Pourreyron, C., Hervieu, V., Poncet, G., Lombard-Bohas, C., Chayvialle, J.A., et al., 2003. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology, 125(4):1094-1104.

[12] Medina, J., Arroyo, A.G., Sanchez-Madrid, F., Moreno-Otero, R., 2004. Angiogenesis in chronic inflammatory liver disease. Hepatology, 39(5):1185-1195.

[13] Sharma, S., Sharma, M.C., Sarkar, C., 2005. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology, 46(5):481-489.

[14] Thorgeirsson, S.S., Lee, J.S., Grisham, J.W., 2006. Functional genomics of hepatocellular carcinoma. Hepatology, 43(2 Suppl 1):S145-150.

[15] Zerbini, A., Pilli, M., Ferrari, C., Missale, G., 2006. Is there a role for immunotherapy in hepatocellular carcinoma? Dig. Liver Dis., 38(4):221-225.

[16] Zhou, L., Liu, J., Luo, F., 2006. Serum tumor markers for detection of hepatocellular carcinoma. World J. Gastroenterol., 12(8):1175-1181.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE